Prothena Reports First Quarter 2026 Financial Results and Business Highlights
Prothena swung to a Q1 profit of $32.7 million, or $0.60 per share, driven by a $50 million milestone payment from partner Novo Nordisk for the Fast Track designation of coramitug. The company significantly tightened its full-year cash burn guidance to $18-23 million from a prior range of $50-55 million, extending its cash runway.
Key figures
- Eps
- 0.6
- Revenue
- 51084000
- Guidance
- FY2026 net cash used in operating and investing activities $18-23M (vs prior $50-55M); expected year-end cash position ~$273M (midpoint).
- Net income
- 32721000
- Ga expenses
- 12666000
- Rd expenses
- 12627000
- Cash position
- 330300000
- Shares repurchased
- 788990
- Share repurchase spend
- 7300000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.